This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
CVS Health (CVS) Stock Moves -1.66%: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $70.69, marking a -1.66% move from the previous day.
Buy Amazon (AMZN) Stock on the Dip Heading into 2019?
by Benjamin Rains
Amazon (AMZN) stock has fallen over 16% in the last three months as part of the larger market pullback driven by the likes of Apple (AAPL) and other giants. The company's days of 40% top-line growth might also be over. But let's dive into Amazon's overall business picture and outlook to see if investors should buy AMZN stock heading into 2019.
CVS Health Aetna Synergy Impressive, PBM Selling Season Solid
by Zacks Equity Research
CVS Health (CVS) estimates a $750-million earning from near-term synergies with low- to mid-single digit addition in the second year after the closure of Aetna transaction.
The Zacks Analyst Blog Highlights: UnitedHealth, Broadcom, CVS Health, FedEx and Oracle
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, Broadcom, CVS Health, FedEx and Oracle
Here's What to Expect from Facebook (FB) Stock in 2019
by Benjamin Rains
Facebook's (FB) 2018 might be a year investors want to forget. But the social media powerhouse will hopefully use it as a lesson to help move forward. The question now is what should we expect from Facebook in 2019?
Top Analyst Reports for UnitedHealth, Broadcom & CVS Health
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), Broadcom (AVGO) and CVS Health (CVS).
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $73.34 in the latest trading session, marking a -1.01% move from the prior day.
Why Is CVS Health (CVS) Up 0.2% Since Last Earnings Report?
by Zacks Equity Research
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mixed Trade War Signals, the Moonves Scandal, & CVS' Drug Price Plan
by Ryan McQueeney
Ryan McQueeney discusses the latest drama in the U.S.-China trade war, new developments in Les Moonves' departure from CBS, and a new drug pricing plan from pharmacy giant CVS.
CVS Health (CVS) Stock Moves -0.77%: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $78.91 in the latest trading session, marking a -0.77% move from the prior day.
Buy Walgreens (WBA) Stock on Expanded Kroger (KR) Partnership?
by Benjamin Rains
Shares of Walgreens Boots Alliance (WBA) touched a new 52-week high Tuesday morning as investors began to digest the possibilities of what its partnership with grocery power Kroger (KR) might do to boost traffic as it expands its reach in the quickly changing retail age.
Should You Buy Kroger (KR) Stock Before Q3 Earnings?
by Benjamin Rains
Let's see what to expect from Kroger to understand if KR stock might be worth buying.
CVS Health Closes Aetna Deal, Focuses More on Pharmacy Wing
by Zacks Equity Research
The joint entity of CVS Health (CVS) and Aetna will provide customers with the powerful health resources of the former and the latter's network of providers for quality care.
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $80.27, moving +0.97% from the previous trading session.
Company News For Nov 27, 2018
by Zacks Equity Research
Companies In The News Are: ZFGN,CLF,AET,CVS,GWPH
CVS Health (CVS) Gets Final Approval to Close Aetna Deal
by Zacks Equity Research
Both CVS Health (CVS) and Aetna are hopeful about this consolidation, which is aimed at revolutionizing consumer health care experience and substantial cost reduction.
4 Stocks to Buy as US Labor Market Reaches Full Potential
by Zacks Equity Research
An overly tight labor market could push wages up further, increasing consumer optimism around spending.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $75.07, marking a -0.6% move from the previous day.
Near-Term Outlook for Health Maintenance Organization Industry
by Zacks Equity Research
Retiring baby boomer population, new streams of revenues and consolidation paint a bright picture for the HMO industry.
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $80.34 in the latest trading session, marking a +0.64% move from the prior day.
CVS Health's (CVS) Q3 Earnings Top Estimate, Gross Margin Up
by Zacks Equity Research
CVS Health's (CVS) year-over-year growth in the top line was driven by a strong Pharmacy Services segment, benefiting from the upside in the specialty services.
Will Stocks Gain After the Elections? & Earnings from CVS, LLY, HEAR
by Ryan McQueeney
Ryan McQueeney chats with Dave Bartosiak about the near-term outlook for stocks after the midterm elections and the earnings outlook for Turtle Beach ahead of its report. The host also recaps earnings results from CVS, Eli Lilly, and Regeneron.
Stocks Gain Ahead of Midterm Results, But Where Are They Headed Next?
by Ryan McQueeney
U.S. stocks opened modestly higher on Tuesday, as investors kept a watchful eye on the historically tense midterm elections. Here's what market strategists are saying will happen after the midterms.
September JOLTS Report In Spotlight
by Zacks Equity Research
September JOLTS Report In Spotlight
Playing the Waiting Game; Plus MedTech, Pharma in Q3 Earnings
by Mark Vickery
We won't get the final numbers until later, so until then we're just playing the waiting game.